Zoniporide mesylate

Zoniporide (1 nM‑100 μM; 6 min) mesylate (CP-597396 mesylate) potently inhibits human NHE-1-mediated ²²Na⁺ uptake in PS120 fibroblast cells with an IC₅₀ of 14 nM^[2].
Zoniporide (1 nM‑100 μM; 6 min) mesylate inhibits human NHE-2-mediated ²²Na⁺ uptake in PS120 fibroblast cells with an IC₅₀ of 2.2 μM, showing 157-fold lower potency than for human NHE-1^[2].
Zoniporide (1 nM‑100 μM; 6 min) mesylate inhibits rat NHE-3-mediated ²²Na⁺ uptake in PS120 fibroblast cells with an IC₅₀ of 220 μM, showing 15,700-fold lower potency than for human NHE-1^[2].
Zoniporide (1 nM‑100 μM) mesylate potently inhibits endogenous NHE-1-mediated swelling in human platelet-rich plasma with an IC₅₀ of 0.059 μM^[2].
Zoniporide (compound 3d) mesylate potently and selectively inhibits human NHE-1 (IC₅₀ = 59 nM) in transfected fibroblasts^[3].
Zoniporide (0.001-1.0 μM; 8 min at 25°C; 0.01-1.0 μM; 8 min at 37°C) mesylate potently inhibits native NHE1 activity in adult rat ventricular myocytes with an IC₅₀ of 73 nM at 25°C, and retains comparable inhibitory potency at 37°C^[4].
Zoniporide (0.001-1.0 μM; 5 min) mesylate potently inhibits native NHE1 activity in adult rat platelets with an IC₅₀ of 67 nM^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.